Idexx Laboratories (IDXX) Stock
Leading provider of veterinary and water diagnostic tests. Here's the price, business snapshot, and what's worth knowing about Idexx Laboratories in July 2026.
IDEXX Laboratories is a leading provider of diagnostic tests, instruments and software for the animal health and water testing markets. The company sells a mix of instruments and high-margin consumables as well as practice-management and diagnostic software that together create recurring revenue streams and close customer relationships with veterinary clinics and laboratories. IDEXX benefits from structural trends such as rising pet ownership and increased spending on companion animal care, while also operating in water and livestock testing markets. Investors should note it is exposed to competitive pressures, regulatory requirements and technological change, and its performance can vary with regional veterinary spending and currency moves. The company’s market cap (around $51 billion) reflects sizeable scale and long-term growth expectations, but this is general information only and not personal financial advice — suitability depends on your goals, risk tolerance and timeframe.
Why It’s Moving
IDXX Stock Surges on Q2 Earnings Beat and Accelerating Pandemic Pet Cohort Demand for 2026
- Q2 EPS of $3.94 beat analyst consensus of $3.47, demonstrating immediate pull-through from the installed InVue Dx base and validating the 8% organic revenue floor.
- Management raised full-year 2026 revenue guidance to $4.675 billion–$4.760 billion, with EPS outlook increasing to $14.45–$14.90, reflecting accelerated demand beyond prior estimates.
- Analysts highlighted that the 2026 growth trajectory is heavily supported by the pandemic pet cohort, which is expected to drive sustained recurring revenue and lift the next 14 months of projected earnings.
- Sentiment_tag": "Bullish"}
IDXX Stock Surges on Q2 Earnings Beat and Accelerating Pandemic Pet Cohort Demand for 2026
- Q2 EPS of $3.94 beat analyst consensus of $3.47, demonstrating immediate pull-through from the installed InVue Dx base and validating the 8% organic revenue floor.
- Management raised full-year 2026 revenue guidance to $4.675 billion–$4.760 billion, with EPS outlook increasing to $14.45–$14.90, reflecting accelerated demand beyond prior estimates.
- Analysts highlighted that the 2026 growth trajectory is heavily supported by the pandemic pet cohort, which is expected to drive sustained recurring revenue and lift the next 14 months of projected earnings.
- Sentiment_tag": "Bullish"}
When is the next earnings date for IDEXX LABORATORIES INC (IDXX)?
The next earnings report for IDEXX Laboratories (IDXX) is projected to be released on August 3, 2026, covering the second quarter of 2026 (Q2 2026). This date aligns with the company's historical reporting schedule, as the company has not yet officially confirmed a specific publication time. Investors should expect the announcement to occur before the market opens, consistent with the firm's typical pattern for quarterly releases. Please note that this projection is an estimate based on past data and does not constitute a confirmed official date until the company issues a formal announcement.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IDEXX Laboratories' stock with a target price of $771.46, showing growth potential.
Financial Health
IDEXX Laboratories is generating strong revenue and cash flow, indicating good financial performance overall.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring IDXX
Food Safety Stocks: What's Next After Costco Lawsuit
A recent lawsuit against Costco regarding salmonella in its rotisserie chicken has intensified focus on food safety across the grocery industry. This creates a potential investment opportunity in companies that provide testing, diagnostics, and supply chain verification services.
Published: 15 February 2026
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: 11 August 2025
Explore BasketPets Are Family
The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady Consumables Demand
High-margin consumables and recurring test volumes can support predictable revenue, though demand may fluctuate with vet clinic activity.
Global Pet Care Trends
Growing pet ownership and higher veterinary spending provide long-term tailwinds, while international expansion adds opportunity and exposure to currency risk.
Innovation & Software
Diagnostics instruments and practice-management software help differentiate the offering, yet product cycles and competition create execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
